ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Takara Bio Inc.

Business Summary

Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. It provides products and services for basic research and industrial application in life sciences. These include services for the research and manufacturing of regenerative medicine products and the development of gene therapy products for synovial sarcoma. It also develops, manufactures, and sells reagents for polymerase chain reaction (PCR) tests for COVID-19. The company was founded on April 1, 2002 and is headquartered in Kusatsu, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue46,086M434.53M
Gross Profit30,909M291.43M
Operating income13,953M131.56M
Income before tax13,552M127.77M
Net income9,547M90.01M
EBITDA17,739M167.25M
Diluted EPS79.280.74
Dividends Per Share160.15
Total Assets90,982M823.36M
Total liabilities16,678M150.93M
Total equity74,182M671.33M
Operating cash flow13,943M131.46M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 29,375M 32,312M 35,841M 34,565M 46,086M
Gross Profit 16,387M 18,079M 20,179M 20,519M 30,909M
Operating income 3,204M 3,556M 5,465M 6,276M 13,953M
Income before tax 2,805M 3,361M 4,823M 5,433M 13,552M
Net income 1,353M 2,335M 3,658M 3,820M 9,547M
EBITDA 5,253M 6,773M 8,840M 9,806M 17,739M
Diluted EPS 11.22 19.39 30.37 31.71 79.28
Dividends Per Share 4 4.50 7 8 16
Total Assets 67,143M 70,237M 72,517M 76,343M 90,982M
Total liabilities 7,154M 8,278M 8,421M 9,751M 16,678M
Total equity 59,885M 61,853M 64,010M 66,496M 74,182M
Operating cash flow 3,584M 3,935M 5,783M 6,339M 13,943M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 271.26M 291.53M 323.19M 317.90M 434.53M
Gross Profit 151.32M 163.12M 181.96M 188.72M 291.43M
Operating income 29.58M 32.08M 49.28M 57.72M 131.56M
Income before tax 25.90M 30.32M 43.49M 49.96M 127.77M
Net income 12.49M 21.06M 32.98M 35.13M 90.01M
EBITDA 48.50M 61.11M 79.71M 90.19M 167.25M
Diluted EPS 0.10 0.17 0.27 0.29 0.74
Dividends Per Share 0.03 0.04 0.06 0.07 0.15
Total Assets 602.55M 660.43M 655.16M 707.17M 823.36M
Total liabilities 64.20M 77.83M 76.08M 90.32M 150.93M
Total equity 537.42M 581.59M 578.30M 615.96M 671.33M
Operating cash flow 33.09M 35.50M 52.14M 58.30M 131.46M

Valuation Measures

Mar 2021
PER37.43
ROA11.41%
ROE13.57%
Operating margin30.27%
Profit margin20.71%

Key executives

  • President & Representative Director: Koichi Nakao
  • COO, Director & Senior Managing Executive Officer: Junichi Mineno
  • CFO, Representative Director & Executive VP: Shuichiro Matsuzaki
  • Executive Officer & GM-Business Administration: Takuya Kakemi
  • Executive Officer & Manager-CDM Center 4: Masanari Kitagawa

Shareholders

  • Takara Holdings Inc. (60.9%)
  • Nomura Asset Management Co., Ltd. (1.3%)
  • Shiozumi Asset Management Co. Ltd. (1.1%)
  • JPMorgan Asset Management (Asia Pacific) Ltd. (1.1%)
  • The Vanguard Group, Inc. (1.0%)
  • JPMorgan Asset Management (UK) Ltd. (0.6%)
  • Nikko Asset Management Co., Ltd. (0.6%)
  • Daiwa Asset Management Co. Ltd. (0.6%)
  • Norges Bank Investment Management (0.5%)
  • BlackRock Fund Advisors (0.4%)

Contact Details

Related Companies

  • Cellectis AB
  • DSS Takara Bio India Pvt Ltd.
  • Takara Korea Biomedical, Inc.
  • Takara Biomedical Technology (Beijing) Co., Ltd.
  • TaKara Biotechnology (Dalian) Co., Ltd.
  • Takara Bio USA Holdings, Inc.
  • M's Science Corp. /Anti-Cancer Drug Division/
  • Takara Bio Europe SAS
  • Takara Bio Employee Stock Ownership Plan
  • Takara Bio Europe AB
  • Takara Bio USA, Inc.

Competitors

  • ZIOPHARM Oncology, Inc.
  • Cellid Co., Ltd.
  • Immunocore Holdings Plc Sponsored ADR
  • Phio Pharmaceuticals Corp.
  • Vaxart, Inc.
Last Updated on 16 Sep, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more